Exenatide long-acting release - AstraZeneca

Drug Profile

Exenatide long-acting release - AstraZeneca

Alternative Names: Bydureon; Bydureon Pen; Byetta LAR; Exenatide extended-release for injectable suspension; Exenatide LAR; Exenatide once-weekly suspension; Ready to Use Exenatide Once Weekly

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Eli Lilly
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 11 Oct 2016 Exenatide long-acting release licensed to Hongkong Sansheng for commercialisation in China
  • 16 Sep 2016 Positive efficacy and adverse events data from the phase III DURATION-8 trial in Type-2 diabetes mellitus (Adjunctive treatment) released by AstraZeneca
  • 01 Aug 2016 AstraZeneca completes a phase-III clinical trial in Type-2 diabetes mellitus (Adjunctive therapy) in USA (SC) (NCT02229383)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top